altera corp (ALTR:NASDAQ GS)
Susan S. Wang
Independent Director and Chairman of Audit Committee, Nektar Therapeutics
|Age||Total Calculated Compensation||This person is connected to 48 board members in 3 different organizations across 9 different industries.|
See Board Relationships
Ms. Susan S. Wang served as the Chief Financial Officer, Executive Vice President of Corporate Development and Corporate Secretary at Solectron Corporation. Ms. Wang retired from Solectron in June 2002 and has held several key positions during her 18 years. She is a Financial Expert. Before joining Solectron in 1984, Ms. Wang held financial and managerial positions with Xerox Corporation , Westvaco Corporation, Price Waterhouse LLP and Price Waterhouse & Co. She has ...
101 Innovation DrivePhone: 408-544-7000
San Jose, California 95134
Board Members Memberships*
Former Director, Chairman of Audit Committee and Member of Compensation Committee
Former Director and Chairman of Audit Committee
Independent Director and Chairman of Audit Committee
Former Independent Director, Chairman of Audit Committee and Member of Executive Committee
Former Independent Director and Chairman of Audit Committee
Former Chairwoman and Member of Audit Committee
Director, Chairperson of Audit Committee and Member of Compensation Committee
Independent Director, Chairman of Audit Committee and Member of Member Agreement Review Committee
The University of Texas System
University of Connecticut
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
|Michael W. Aguiar||Chief Executive Officer, President, Chief Financial Officer, Principal Accounting Officer, Senior Vice President of Finance, Treasurer and Director|
|Peter M. Hecht Ph.D.||Co-Founder, Chief Executive Officer and Director|
Ironwood Pharmaceuticals, Inc.
|James A. Schoeneck||Chief Executive Officer, President and Director|
|George Frederick Wilkinson||Chief Executive Officer, President and Director|
Impax Laboratories Inc.
|Peter S. Greenleaf||Chief Executive Officer, Director, Member of Commercialization Committee and Member of Science & Technology Committee|
Sucampo Pharmaceuticals, Inc.
|--||Compensation as of Fiscal Year 2013.|